

Selvita to Present its Oncology Data at SITC 2018

01 November 2018 | News

Data presented at the conference will include recent results from Selvita's discovery phase project targeting cancer immunometabolism a dual A2A/A2B adenosine receptor antagonist, as well as cancer immunotherapy



Selvita a clinical stage drug discovery and development company focused on innovative medicines for oncology patients, will publish the most recent data from its oncology programs at the 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC), which will take place on November 7–11, 2018 at the Walter E. Washington Convention Center in Washington, D.C., USA.

Data presented at the conference will include recent results from Selvita's discovery phase project targeting cancer immunometabolism a dual A2A/A2B adenosine receptor antagonist, as well as cancer immunotherapy – a novel class of small molecule direct STING agonists.

"We look forward to present new results from our early discovery projects. We see our immunometabolism and immunooncology programs as key assets in Selvita's pipeline. Therefore we are excited to share the data demonstrating potent, next-generation small molecule STING agonists as well as a series of dual A2A/A2B antagonists retaining its nanomolar potency in tumor-like adenosine rich environment" said Krzysztof Brzózka, Chief Scientific Officer at Selvita.

SITC 2018 brings together a unique and international mix of pharmaceutical and biotech companies, leading universities and clinical research institutions in the cancer immunotherapy area. It provides a multidisciplinary educational and interactive environment focused on improving outcomes for current and future patients with cancer by incorporating strategies based on basic and applied cancer immunotherapy.